These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

882 related items for PubMed ID: 22351686

  • 21. Sphingosine kinase 1 regulates the Akt/FOXO3a/Bim pathway and contributes to apoptosis resistance in glioma cells.
    Guan H, Song L, Cai J, Huang Y, Wu J, Yuan J, Li J, Li M.
    PLoS One; 2011; 6(5):e19946. PubMed ID: 21625639
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6.
    Yoshida A, Lee EK, Diehl JA.
    Cancer Res; 2016 May 15; 76(10):2990-3002. PubMed ID: 26988987
    [Abstract] [Full Text] [Related]

  • 24. Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells.
    Azimi A, Tuominen R, Costa Svedman F, Caramuta S, Pernemalm M, Frostvik Stolt M, Kanter L, Kharaziha P, Lehtiö J, Hertzman Johansson C, Höiom V, Hansson J, Egyhazi Brage S.
    Cell Death Dis; 2017 Aug 31; 8(8):e3029. PubMed ID: 29048432
    [Abstract] [Full Text] [Related]

  • 25. Gefitinib-resistance is related to BIM expression in non-small cell lung cancer cell lines.
    Li H, Zhou S, Li X, Wang D, Wang Y, Zhou C, Schmid-Bindert G.
    Cancer Biother Radiopharm; 2013 Mar 31; 28(2):115-23. PubMed ID: 23270470
    [Abstract] [Full Text] [Related]

  • 26. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.
    Mao M, Tian F, Mariadason JM, Tsao CC, Lemos R, Dayyani F, Gopal YN, Jiang ZQ, Wistuba II, Tang XM, Bornman WG, Bollag G, Mills GB, Powis G, Desai J, Gallick GE, Davies MA, Kopetz S.
    Clin Cancer Res; 2013 Feb 01; 19(3):657-67. PubMed ID: 23251002
    [Abstract] [Full Text] [Related]

  • 27. The BH3-only protein Bim plays a critical role in leukemia cell death triggered by concomitant inhibition of the PI3K/Akt and MEK/ERK1/2 pathways.
    Rahmani M, Anderson A, Habibi JR, Crabtree TR, Mayo M, Harada H, Ferreira-Gonzalez A, Dent P, Grant S.
    Blood; 2009 Nov 12; 114(20):4507-16. PubMed ID: 19773546
    [Abstract] [Full Text] [Related]

  • 28. Identification of NRAS isoform 2 overexpression as a mechanism facilitating BRAF inhibitor resistance in malignant melanoma.
    Duggan MC, Stiff AR, Bainazar M, Regan K, Olaverria Salavaggione GN, Maharry S, Blachly JS, Krischak M, Walker CJ, Latchana N, Tridandapani S, de la Chapelle A, Eisfeld AK, Carson WE.
    Proc Natl Acad Sci U S A; 2017 Sep 05; 114(36):9629-9634. PubMed ID: 28827320
    [Abstract] [Full Text] [Related]

  • 29. Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells.
    Shao Y, Aplin AE.
    Cancer Res; 2010 Aug 15; 70(16):6670-81. PubMed ID: 20647317
    [Abstract] [Full Text] [Related]

  • 30. Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors.
    Azimi A, Caramuta S, Seashore-Ludlow B, Boström J, Robinson JL, Edfors F, Tuominen R, Kemper K, Krijgsman O, Peeper DS, Nielsen J, Hansson J, Egyhazi Brage S, Altun M, Uhlen M, Maddalo G.
    Mol Syst Biol; 2018 Mar 05; 14(3):e7858. PubMed ID: 29507054
    [Abstract] [Full Text] [Related]

  • 31. 8‑bromo‑7‑methoxychrysin induces apoptosis by regulating Akt/FOXO3a pathway in cisplatin‑sensitive and resistant ovarian cancer cells.
    Ding Q, Chen Y, Zhang Q, Guo Y, Huang Z, Dai L, Cao S.
    Mol Med Rep; 2015 Oct 05; 12(4):5100-8. PubMed ID: 26151347
    [Abstract] [Full Text] [Related]

  • 32. Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival.
    Cartlidge RA, Thomas GR, Cagnol S, Jong KA, Molton SA, Finch AJ, McMahon M.
    Pigment Cell Melanoma Res; 2008 Oct 05; 21(5):534-44. PubMed ID: 18715233
    [Abstract] [Full Text] [Related]

  • 33. BH3-only protein Bim more critical than Puma in tyrosine kinase inhibitor-induced apoptosis of human leukemic cells and transduced hematopoietic progenitors carrying oncogenic FLT3.
    Nordigården A, Kraft M, Eliasson P, Labi V, Lam EW, Villunger A, Jönsson JI.
    Blood; 2009 Mar 05; 113(10):2302-11. PubMed ID: 19064725
    [Abstract] [Full Text] [Related]

  • 34. 17-AAG inhibits vemurafenib-associated MAP kinase activation and is synergistic with cellular immunotherapy in a murine melanoma model.
    Joshi SS, Jiang S, Unni E, Goding SR, Fan T, Antony PA, Hornyak TJ.
    PLoS One; 2018 Mar 05; 13(2):e0191264. PubMed ID: 29481571
    [Abstract] [Full Text] [Related]

  • 35. The HSP90 inhibitor, XL888, enhanced cell apoptosis via downregulating STAT3 after insufficient radiofrequency ablation in hepatocellular carcinoma.
    Sun C, Bai M, Ke W, Wang X, Zhao X, Lu Z.
    Life Sci; 2021 Oct 01; 282():119762. PubMed ID: 34186047
    [Abstract] [Full Text] [Related]

  • 36. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.
    Greger JG, Eastman SD, Zhang V, Bleam MR, Hughes AM, Smitheman KN, Dickerson SH, Laquerre SG, Liu L, Gilmer TM.
    Mol Cancer Ther; 2012 Apr 01; 11(4):909-20. PubMed ID: 22389471
    [Abstract] [Full Text] [Related]

  • 37. TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma.
    Corcoran RB, Rothenberg SM, Hata AN, Faber AC, Piris A, Nazarian RM, Brown RD, Godfrey JT, Winokur D, Walsh J, Mino-Kenudson M, Maheswaran S, Settleman J, Wargo JA, Flaherty KT, Haber DA, Engelman JA.
    Sci Transl Med; 2013 Jul 31; 5(196):196ra98. PubMed ID: 23903755
    [Abstract] [Full Text] [Related]

  • 38. BIK is involved in BRAF/MEK inhibitor induced apoptosis in melanoma cell lines.
    Borst A, Haferkamp S, Grimm J, Rösch M, Zhu G, Guo S, Li C, Gao T, Meierjohann S, Schrama D, Houben R.
    Cancer Lett; 2017 Sep 28; 404():70-78. PubMed ID: 28720543
    [Abstract] [Full Text] [Related]

  • 39. PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced.
    Jebahi A, Villedieu M, Pétigny-Lechartier C, Brotin E, Louis MH, Abeilard E, Giffard F, Guercio M, Briand M, Gauduchon P, Lheureux S, Poulain L.
    Cancer Lett; 2014 Jun 28; 348(1-2):38-49. PubMed ID: 24650799
    [Abstract] [Full Text] [Related]

  • 40. Quantitative Proteomics Links the Intermediate Filament Nestin to Resistance to Targeted BRAF Inhibition in Melanoma Cells.
    Schmitt M, Sinnberg T, Nalpas NC, Maass A, Schittek B, Macek B.
    Mol Cell Proteomics; 2019 Jun 28; 18(6):1096-1109. PubMed ID: 30890564
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 45.